IP Library Granted Patent US 11,535,827
Granted Patent B2
US 11,535,827 · App. 16/649,476 · Granted Dec 27, 2022

Plated hepatocytes and preparation and uses thereof

Inventors: Jung Bok Lee (Virginia Beach, VA); Angela Murchison (Virginia Beach, VA); Edward LeCluyse (Virginia Beach, VA); Jingsong Chen (Virginia Beach, VA)
Assignee: LifeNet Health
C12N5/067G01N33/5067C12N2502/1323C12N2502/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,535,827
App. No.
16/649,476
Granted
Dec 27, 2022
Kind
B2
Abstract

The present invention provides a product comprising plated human hepatocytes on a surface and at least some of the plated hepatocytes are in one or more hepatocyte clusters on feeder cells, which are attached to the surface. A method of preparing plated human hepatocytes is also provided. The preparation method comprises applying human hepatocytes to a surface in the presence of feeder cells, co-culturing the applied hepatocytes with the feeder cells, and forming one or more hepatocyte clusters by the co-cultured hepatocytes on the feeder cells, which are attached to the surface. The plated hepatocytes may be used for various purposes, including the preparation of a hepatitis B virus (HBV) infected hepatocyte culture model and drug testing.

Claims (21)

1. A product comprising plated human hepatocytes on a surface, wherein at least 70% of the plated hepatocytes are in one or more hepatocyte clusters on feeder cells, wherein the feeder cells are endothelial cells and fibroblasts and are attached to the surface.

2. The product of claim 1 , wherein at least 90% of the plated hepatocytes in the one or more hepatocyte clusters are in direct hepatocyte-hepatocyte contact.

3. The product of claim 1 , wherein the one or more hepatocyte clusters cover at least 50% of the surface.

4. The product of claim 1 , further comprising a culture medium, wherein at least 90% of the plated hepatocytes remain on the surface for at least 7 days.

5. The product of claim 1 , wherein the endothelial cells are not liver cells.

6. The product of claim 1 , wherein the fibroblasts are not liver cells.

7. The product of claim 1 , wherein the plated hepatocytes are obtained from a single donor, and wherein the donor has suffered from microsteatosis.

8. The product of claim 1 , wherein the plated hepatocytes are obtained from a single donor, and wherein the donor has suffered from nonalcoholic steatohepatitis (NASH).

9. A method of preparing plated human hepatocytes, comprising

(a) applying human hepatocytes to a surface in the presence of feeder cells, wherein the feeder cells are endothelial cells and fibroblasts,

(b) co-culturing the applied hepatocytes with the feeder cells after step (a), and

(c) forming one or more hepatocyte clusters by the co-cultured hepatocytes on the feeder cells, wherein the feeder cells are attached to the surface, wherein at least 85% of the co-cultured hepatocytes are in the one or more hepatocyte clusters, whereby plated human hepatocytes are prepared.

10. The method of claim 9 , wherein the applied hepatocytes in step (a) have a platability of less than 60% on the surface in the absence of the feeder cells.

11. The method of claim 9 , wherein the applied hepatocytes in step (a) have a platability of at least 85% on the surface in the absence of the feeder cells.

12. The method of claim 9 , wherein at least 90% of the plated hepatocytes remain on the surface for at least 7 days.

13. The method of claim 9 , wherein the feeder cells are attached to the surface in step (b).

14. The method of claim 9 , wherein the method excludes addition of an extracellular matrix protein.

15. A method of preparing a hepatitis B virus (HBV) infected hepatocyte culture model, comprising

(a) inoculating the plated hepatocytes in the product of claim 1 with hepatitis B virus (HBV), and

(b) incubating the infected plated hepatocytes for at least 14 days, whereby the HBV infected hepatocyte culture model is prepared.

16. The product of claim 1 , wherein the fibroblasts and endothelial cells have 0% to 10% interference in biological activity with the hepatocytes.

Assignments (2)
SECURITY INTEREST Recorded Apr 2, 2021
From: LIFENET HEALTH; SKIN AND WOUND ALLOGRAFT INSTITUTE, LLC
To: TRUIST BANK
Reel/Frame 055815/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2020
From: LEE, JUNG BOK; MURCHISON, ANGELA; LECLUYSE, EDWARD; CHEN, JINGSONG
To: LIFENET HEALTH
Reel/Frame 053224/0260 →